National Heart, Lung, and Blood Institute (NHLBI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Heart, Lung, and Blood Institute (NHLBI) sits in the top decile of US sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count).
National Heart, Lung, and Blood Institute (NHLBI): 501 sponsored US clinical trials, 62 recruiting.
National Heart, Lung, and Blood Institute (NHLBI) sponsors 501 registered US clinical trials on ClinicalTrials.gov, 62 of them currently recruiting, and 381 completed. 33 of these trials are in Phase 3-4 (later-stage) and 205 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atherosclerosis, with 12 trials.
Top-decile sponsor footprint
National Heart, Lung, and Blood Institute (NHLBI) ranks in the top decile of sponsors by registered trial count (#73 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
381 of 417 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
501 total, page 3 of 11
COV2Base-A Rare Disease by COVID Study
NCT04564274
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
NCT04349189
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
NCT04271735
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT04209621
Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7 Abnormalities After Immunosuppressive Therapy
NCT04436367
Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy
NCT04436380
Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy
NCT03958643
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome
NCT03789175
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
NCT03685708
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
NCT03702231
The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects
NCT03565328
Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension
NCT03572036
Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant
NCT03511794
Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging
NCT03478917
Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation
NCT03381989
Transmural Systems Transcaval Closure Device for Transcaval Access Ports During Transcatheter Aortic Valve Replacement
NCT03432494
Discovery of Sirolimus Sensitive Biomarkers in Blood
NCT03304678
dbGaP Protocol: The Pediatric Cardiac Genetics Consortium (PCGC)
NCT03347214
Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
NCT03253692
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT03204188
Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires
NCT03152773
Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients
NCT03226691
Extracellular RNAs in Relation to Cardiometabolic Risk
NCT03225196
RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2
NCT03225183
NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation
NCT03015194
Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults
NCT03043365
Pathophysiology of Acute Pain in Patients With Sickle Cell Disease
NCT03049475
WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study)
NCT02692846
Lung Tissue Research Consortium
NCT02988388
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
NCT02996474
Impact of Elastin Mediated Vascular Stiffness on End Organs
NCT02840448
CADASIL Disease Discovery
NCT02821780
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
NCT02728102
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity
NCT02812238
The National Myelodysplastic Syndromes (MDS) Study
NCT02775383
Effect of Fasting and Refeeding on T-cell Fate
NCT02719899
CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction
NCT02740699
High Image Matrix CT Reconstruction
NCT02610465
Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults
NCT02514070
Effect of Fasting on the Asthma Inflammasome
NCT02471300
Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)
NCT02527447
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
NCT02440464
Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
NCT02345850
Hereditary Parkinson s Disease Natural History Protocol
NCT02511015
dbGaP Protocol: Genetic Variants Associated With Pentalogy of Cantrell
NCT02430376
Effects of Niacin Therapy on Lipoprotein Composition and Function
NCT02322203
Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
NCT02156115
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
NCT02322320
Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids
NCT02379442
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis
NCT02315586
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 118 |
| Phase 3 | 29 |
| Phase 4 | 4 |
Therapeutic Areas
What is open in the National Heart, Lung, and Blood Institute (NHLBI) pipeline
62 recruiting of 501 indexed (12% open); 381 completed (76%).
Phase mix: 33 late (III/IV) vs 205 early (I/II) (early-phase heavy).
Top condition: Atherosclerosis (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Heart, Lung, and Blood Institute (NHLBI): open-pipeline peers nationwide
Peers matched on 501 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
National Heart, Lung, and Blood Institute (NHLBI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 501 trials (± recruiting share)
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- AstraZeneca · 12% recruiting · 1,285 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- University of Iowa · 12% recruiting · 228 trials
Related
What to do with this National Heart, Lung, and Blood Institute (NHLBI) page
501 registered trials is a research-attention snapshot, not an endorsement of National Heart, Lung, and Blood Institute (NHLBI) or any single study.
- 62 of National Heart, Lung, and Blood Institute (NHLBI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atherosclerosis is the condition National Heart, Lung, and Blood Institute (NHLBI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atherosclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Heart, Lung, and Blood Institute (NHLBI) pipeline card: 501 registered trials from official public datasets.Report a data error.